The short answer — and why it matters

For many people with knee osteoarthritis, yes — injection therapy can push back the need for knee replacement, sometimes by a matter of months, in some cases by several years. That is a meaningful answer, but it carries an equally important qualification: no injection currently available has been shown to halt osteoarthritis at the structural level. The honest framing is delay, not prevention.

The patients most likely to see benefit are those with mild-to-moderate disease, where enough joint space and cartilage remain for an injection to have something to work with. In advanced or end-stage disease that biological room contracts sharply, and surgery becomes the more realistic path — a distinction that shapes every conversation in the sections that follow.

Within those limits, injections serve a genuine purpose: reducing pain, preserving day-to-day function, and buying time for other conservative measures — physiotherapy, weight management, activity modification — to contribute. The goal is a longer functional window, not a cure.

Where injections fit in the knee OA pathway

Knee OA management follows a broadly sequential pathway: conservative care first — physiotherapy, weight management, and analgesia — then injection therapy, and, if symptoms continue to progress beyond what either stage can manage, surgical intervention. Injections occupy that third position, functioning as a bridge rather than an endpoint in their own right.

The clinical trigger for moving to injections is functional, not radiological. Imaging grade and symptom burden do not always track each other: some patients with moderate X-ray changes report severe daily limitation; others with advanced structural findings remain well-managed on physiotherapy alone. A specialist assessment weighs both — alongside age, activity level, and overall health — before matching the right injection agent to the individual's clinical picture. It also rules out other causes of knee pain that injections would not address, such as referred pain from the hip or spine, or an underlying inflammatory arthritis.

This pathway applies specifically to chronic degenerative knee OA. Acute inflammatory joint disease and post-traumatic presentations follow different decision trees, and the delay evidence discussed in later sections does not extend to those groups.

Hyaluronic acid — the strongest delay signal

The most direct evidence for injection-related TKR delay comes from hyaluronic acid (HA), or viscosupplementation. A 2015 study by Altman et al., drawing on US insurance claims from 182,022 patients who eventually underwent total knee replacement, found that those who had received at least one HA course waited a median of 484 days before surgery — compared with 114 days for those who received none. That roughly one-year gap is the clearest delay signal in the published literature for any injection type.

The dose-response relationship strengthens the picture. Patients who completed four or more HA treatment episodes waited a median of approximately 1,009 days — close to three years — before surgery. In practice, a single HA course typically involves three to five injections given over several weeks; repeating that course, generally at six-to-twelve-month intervals, appears to compound the benefit.

The study's limits deserve acknowledgement. Being observational, it cannot rule out the possibility that patients selected for HA were already on a slower disease trajectory — whether because of milder OA, stronger adherence to other treatments, or unmeasured confounders. No RCT has yet used surgery avoidance as a primary outcome for HA, so the delay cannot be attributed to the injection alone with certainty.

What the evidence does support is that HA, used consistently across multiple courses, is associated with a clinically meaningful postponement — and for patients asking how much time injections might buy, it currently offers the most relevant numbers available.

Corticosteroids — fast relief with a practical constraint

Corticosteroid injections earn their place in the treatment pathway for one reason: they work quickly. For patients in the grip of an acute OA flare — swollen, inflamed, struggling with basic daily movement — a steroid injection can deliver meaningful pain relief within days, with evidence supporting a benefit window of roughly 6 to 12 weeks. That speed makes them a reliable option when symptoms need controlling fast.

What steroids do not do is alter the joint's underlying condition. There is no robust clinical evidence that they slow cartilage loss, reduce structural deterioration, or push back the need for knee replacement. Used frequently at high doses, they may in fact carry the opposite risk: some evidence suggests accelerated cartilage breakdown with repeated corticosteroid exposure. This positions them firmly as an acute symptom-management tool rather than a joint-preservation strategy.

The 90-day planning rule

For anyone who may be approaching surgery, there is one practical constraint that needs to be understood clearly. Surgeons require a minimum 90-day gap between a corticosteroid injection and a total knee replacement. The reason is infection risk: steroids temporarily suppress local immune activity, and operating on a joint too soon after an injection meaningfully raises the chance of a serious post-surgical infection. This is standard guidance across orthopaedic practice, not an unusual individual preference.

The planning implication is real. A patient who has a steroid injection today and then decides they want surgery cannot proceed for at least three months. For patients who are already in the pre-surgical phase, that timing decision deserves careful thought before committing to another steroid course. Discussing the likely surgical timeline with a clinician before arranging the injection is the sensible order of events.

PRP and newer agents — promising signals, unresolved questions

Platelet-rich plasma (PRP) is where the evidence becomes genuinely contested — and intellectual honesty requires naming that tension rather than smoothing it over.

On one side sits a retrospective study by Sánchez et al. (2021), which reported that 74.1% of patients receiving PRP injections delayed knee replacement by more than 1.5 years, with a median delay of 5.3 years. Those are striking numbers. On the other side sits a randomised controlled trial by Bennell et al., published in JAMA in 2021 and cited nearly 500 times, which found that PRP did not significantly outperform placebo for either knee pain or cartilage volume loss at 12 months. That is the highest-quality contradictory signal in the field, and it cannot be set aside.

The gap between the two findings is most plausibly explained by selection bias in the retrospective data — patients who received PRP may have been healthier, more engaged in their overall care, or at an earlier disease stage than typical surgical candidates. Comparative reviews do tend to favour PRP over corticosteroids and HA for symptom control, but that symptomatic advantage has not translated into proven structural modification in controlled settings. Where PRP stands on the delay question genuinely remains open.

Arthrosamid — a different category

Arthrosamid (injectable polyacrylamide hydrogel, iPAAG) represents a distinct approach: rather than a drug or biologic, it functions as a permanent scaffold and lubricant within the joint, intended to restore cushioning and reduce mechanical load. An open-label study by Bliddal et al. (2024) supported 12-month safety and efficacy, and manufacturer-cited data suggest sustained benefit for up to five years, with a reported success rate exceeding 70% for pain reduction. Arthrosamid is positioned between physiotherapy and surgery in the treatment pathway.

No randomised controlled trial has yet measured TKR delay as a primary outcome for Arthrosamid, so the controlled evidence base remains early-stage. Both PRP and Arthrosamid may offer real benefit for the right patient, but neither can currently be described as a confirmed solution for delaying knee replacement.

Deciding when to stop injections and consider surgery

The point at which injections give way to surgery emerges from reading a pattern, not from counting courses. A single injection that underperforms is not a signal; three or four whose effect lasts progressively fewer weeks, each leaving the joint symptomatic and functionally limited between cycles, is a different picture entirely. The practical markers are consistent: relief that diminishes with each episode, a return to significant functional restriction between cycles, and quality of life that stays impaired despite treatment.

Disease stage matters alongside symptom trajectory. In advanced osteoarthritis where cartilage loss is near-complete, no injection has biological room to work. Imaging and clinical assessment together establish whether the joint has reached that threshold — neither alone is sufficient.

On timing before surgery: the 90-day corticosteroid minimum (covered above) remains a live constraint for surgical planning. For HA, PRP, and similar agents, 3–6 months is the general guide before proceeding, allowing adequate assessment of what the injection contributed and time for the joint to settle.

The Altman dose-response data make one implication difficult to ignore. Patients who completed four or more HA treatment episodes waited a median of roughly 1,009 days before surgery — nearly three years. A patient now reaching a sixth or seventh episode that produces four weeks of relief where earlier courses delivered four months is probably near the natural end of that window, not its beginning. A specialist assessment — examining symptom trajectory, imaging, and functional status together — is what translates that specific signal into a concrete surgical plan for that individual.

Injections have done their work when they have bought meaningful time and preserved function. The move towards surgery is a continuation of that strategy, not its collapse.